New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 15, 2012
07:34 EDTHZNPHorizon Pharma's SkyeParma: USPTO issues notice of allowance for RAYOS tablets
Horizon Pharma announced that SkyePharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 2012/0177734 entitled "Delayed Release Tablet with Defined Core Geometry" that covers the U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The patent scheduled to issue from this application will expire in 2024 for the U.S. patent. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Horizon CEO Timothy P. Walbert commented: "This patent allowance is a critical expansion of the patent estate for RAYOS. We are focused on protecting the commercial potential of RAYOS to 2024 and we will begin the RAYOS commercial launch this quarter."
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
07:42 EDTHZNPPOZEN receives three patents from USPTO
POZEN (POZN) announced that it has received three patents from the United States Patent and Trademark Office, entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that cover the U.S. approved product VIMOVO. All three patents are expected to expire in 2022. Horizon Pharma (HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list U.S. patents 8,858,996 and 8,852,636 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use